Sign in
CompletedPhase 3

Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata

Key facts

Who runs it
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Where
China2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
425 people enrolled
Started
4 Sept 2021
Ended
27 Dec 2023
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Jaktinib
  • placebo
Record updated
14 March 2025

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (7)Hide the full registry criteria

Who can take part

  • participants voluntarily sign the informed consent form (ICF)
  • Age ≥ 18 years and <65 years, either male or female
  • Clinical presentation compatible with alopecia areata with a current episode lasting not exceeding ≤8 years
  • At least 50% scalp hair loss
  • Willing to comply with the study visits and requirements of the study protocol

Who cannot take part

  • participants has taken a JAK inhibitor prior to randomization
  • participants who are unsuitable to the trial, as identified by the investigator

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a multi-center Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called Jaktinib) in adults (≥18 years and <65 years) who have 50% or greater scalp hair loss. The study is placebo-controlled, meaning that some patients entering the study will not receive active study drug but will receive tablets with no active ingredients (a placebo). It is double-blinded, meaning that the Sponsor, the study doctors, the staff, and the patients will not know whether a patient is on active study drug (or the dose) or placebo.

The 3 groups in the trial

  • Jaktinib 50mg BIDTreatment being tested

    Participants received Jaktinib 50mg tablets, orally, twice daily (BID) for up to 24 weeks.

    Treatment: Jaktinib

  • Jaktinib 75mg BIDTreatment being tested

    Participants received Jaktinib 75mg tablets, orally, twice daily (BID) for up to 24 weeks.

    Treatment: Jaktinib

  • placeboPlacebo, for comparison

    Participants received Jaktinib matched placebo tablets, orally, twice daily (BID) for up to 24 weeks.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Jaktinib in Adult Patients With Severe Alopecia Areata
Record updated
14 March 2025